20-310 - Extension Study To Evaluate Safety And Tolerability Of 24-Hour Daily Exposure Of Continuous Subcutaneous Infusion of ABBV-951 In Adult Participants With Parkinson's Disease
Status: openAn Open-label Extension of Study M15-741 to Evaluate the Safety and Tolerability of 24-hour Daily Exposure of Continuous Subcutaneous Infusion of ABBV-951 in Subjects With Parkinson's Disease
Treatment for Parkinson's Disease
Description
This is an extension study to the M15-736 trial for those participating in that trial. Patients who met criteria to enroll in the parent trial also meet criteria to participate in this 96 week long term safety study of the 24 hour continuous infusion of ABBV-951.
Sponsors
This trial is sponsored by AbbVie.Interested in Clinical Trial?
Contact the Clinical Trial Coordinator
If you have questions get in touch with this Clinical Trial’s Coordinator by phone at +1 (251) 665-8375 or by email at dlwilliams@health.southalabama.edu.
